Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
China Golden Classic Group Limited (8281.HK)
Jiangyin, CN
China Golden Classic Group Limited operates as an investment holding company, primarily engaged in the production and distribution of oral care, leather care, and household hygiene products. Its market presence extends across China, the United States, Australia, and various other international regions. The company's oral hygiene offerings encompass a range of items such as functional toothpaste, mouthwash, oral sprays, and toothbrushes. Beyond dental products, it also specializes in manufacturing and selling diverse leather maintenance solutions, including specific products designed for shoes and apparel. Furthermore, its household product portfolio features surface cleaners, laundry care essentials, toilet sanitation products, and anti-mould treatments. Established in 2015, the firm maintains its headquarters in Jiangyin, located within the People's Republic of China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.85% | -3.85% | -3.85% | +138.10% | +142.72% | +150.00% | +303.23% | +17.92% | +25.00% | -42.53% | -42.53% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Household & Personal Products: +3.3%+2.8% Q4'25: -0.8% (vs Q4'24)
-
EPS growth Household & Personal Products: +8.8%+240.0% ★ Q4'25: +45.7% (vs Q4'24)
-
FCF margin FCF growth · Household & Personal Products: +44.8%+3.5% Q4'25: +31.1% (vs Q4'24)
-
EBIT margin Household & Personal Products: +9.9%+2.3% Q4'25: +6.9% (vs Q4'24)
-
ROIC Household & Personal Products: +8.2%+2.9% Q4'25: +10.7% (vs Q4'24)
-
Share dilution Household & Personal Products: +0.2%+0.0% Q4'25: +0.0% (vs Q4'24)
-
Debt / EBITDA Net debt/EBITDA · Household & Personal Products: -0.51×0.08× ★ Q4'25: 0.05× (vs Q4'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 | 4/5 | 5/5 |
| 2026-05-28 | A | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 | 4/5 | 5/5 |
| 2026-05-27 | A | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 | 4/5 | 5/5 |
| 2026-05-26 | A | 4/5 | 4/5 | 2/5 | 3/5 | 4/5 | 4/5 | 5/5 |
| 2026-05-22 | A | 4/5 | 4/5 | 2/5 | 3/5 | 4/5 | 4/5 | 5/5 |
| 2026-05-21 | A | 4/5 | 4/5 | 2/5 | 3/5 | 4/5 | 4/5 | 5/5 |
| 2026-05-20 | A | 4/5 | 4/5 | 2/5 | 3/5 | 4/5 | 4/5 | 5/5 |
| 2026-05-19 | A | 4/5 | 4/5 | 2/5 | 3/5 | 4/5 | 4/5 | 5/5 |
| 2026-05-18 | A+ | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 4/5 | 5/5 |
| 2026-05-15 | A | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 4/5 | 5/5 |
| 2026-05-14 | A | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 4/5 | 5/5 |
| 2026-05-13 | A | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 4/5 | 5/5 |
| 2026-05-12 | A | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 4/5 | 5/5 |
| 2026-05-11 | A+ | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 4/5 | 5/5 |
| 2026-05-08 | A | 4/5 | 5/5 | 2/5 | 4/5 | 3/5 | 4/5 | 5/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 2/5 | 4/5 | 3/5 | 4/5 | 5/5 |
| 2026-05-06 | A | 4/5 | 5/5 | 2/5 | 4/5 | 3/5 | 4/5 | 5/5 |
| 2026-05-05 | A | 4/5 | 5/5 | 2/5 | 4/5 | 3/5 | 4/5 | 5/5 |
| 2026-05-04 | A | 4/5 | 5/5 | 2/5 | 4/5 | 3/5 | 4/5 | 5/5 |
| 2026-04-30 | A | 4/5 | 5/5 | 2/5 | 4/5 | 3/5 | 4/5 | 5/5 |
| 2026-04-29 | A | 4/5 | 4/5 | 2/5 | 4/5 | 3/5 | 4/5 | 5/5 |
| 2026-04-28 | A | 4/5 | 4/5 | 2/5 | 4/5 | 3/5 | 4/5 | 5/5 |
| 2026-04-27 | A | 4/5 | 5/5 | 2/5 | 4/5 | 3/5 | 4/5 | 5/5 |
| 2026-04-24 | A | 4/5 | 4/5 | 2/5 | 4/5 | 3/5 | 4/5 | 5/5 |
| 2026-04-23 | A | 4/5 | 4/5 | 2/5 | 4/5 | 3/5 | 4/5 | 5/5 |
| 2026-04-21 | A | 4/5 | 4/5 | 2/5 | 4/5 | 3/5 | 4/5 | 5/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 2/5 | 4/5 | 2/5 | 4/5 | 5/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 2/5 | 4/5 | 2/5 | 4/5 | 5/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Qiuyan Li | Executive Chairman & Compliance Officer | 1M | female |
| Xing Tong | Chief Executive Officer & Executive Director | 572.0K | male |
| Yongwei Du | Executive Director | 351.3K | female |
| Dongliang Xiang | Company Secretary | — | male |
| Liyan Zhu | Chief Financial Officer | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 8281.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
